

Technology Appraisal Committee Meeting (Committee [A])

Minutes: Confirmed

Date and Time: 25th March 2015

Venue: The Royal College of General Practitioners, 30 Euston Square,
London, NW1 2HD

Present:	1. Chair Dr Jane Adam	Present for all notes
	2. Professor Iain Squire	Present for all notes
	3. Dr Jeremy Braybrooke	Present for all notes
	4. Dr Gerardine Bryant	Present for all notes
	5. Mr Adrian Griffin	Present for all notes
	6. Dr Anne McCune	Present for all notes
	7. Dr Mohit Misra	Present for all notes
	8. Dr Ian Lewin	Present for all notes
	9. Dr Brian Shine	Present for all notes
	10. Dr Eldon Spackman	Present for all notes
	11. Professor Olivia Wu	Present for all notes
	12. Mr David Thomson	Present for all notes
	13. Ellen Rule	Present for all notes
	14. Sarah Parry	Present for all notes
	15. Dr Andrew England	Present for all notes
	16. Dr Paul Robinson	Present for all notes
	17. Dr John Watkins	Present for all notes
	18. Dr Graham Ash	Present for all notes
	19. Professor Aileen Clarke	Present for all notes
	20. Mr Stephen Sharp	Present for all notes

In attendance:

Meindert Boysen	Programme Director, National Institute for Health and Care Excellence	Present for all notes
Janet Robertson	Associate Director, National Institute for Health and Care Excellence	Present for all notes
Bijal Joshi	Project Manager, National Institute for Health and Care	Present for all notes

Excellence

Marcia Miller	Technology Appraisal Administrator, National Institute for Health and Care Excellence	Present for all notes
Christian Griffiths	Technical Analyst, National Institute for Health and Care Excellence	Present for all notes
Zoe Charles	Technical Adviser, National Institute for Health and Clinical Excellence	Present for all notes

Clinical Experts

Professor Philp Newsome	Clinical expert nominated by British Society of Gastroenterology and Royal College of Physicians	Present for all notes
Professor Derek Manas		

Patient Experts

	Clinical expert nominated by Novartis	Present for all notes
Mr Richard Hall	Patient expert nominated by Liver 4 Life	Present for all notes
Mr Andrew Langford	Patient expert nominated by the British Liver Trust	Present for all notes

Non-public observers:

Notes

Welcome

1. The Chair welcomed all members of the Committee and other attendees present to the meeting. The Chair reviewed the agenda and timescales for the meeting, which included the appraisals of **Everolimus for preventing organ rejection in liver transplantation [ID559]**.
2. The Chair informed the Committee of the non-public observers at this meeting: Heidi Livingstone,
3. Apologies were received from Professor John McMurray, Alec Miners and Mrs Pamela Rees

Notes from the last meeting

4. Minutes of the last meeting we agreed

Appraisal of Everolimus for preventing organ rejection in liver transplantation [ID559]

Part 1 – Open session

5. The Chair welcomed the invited experts: Mr Richard Hall, Mr Andrew Langford, Professor Philip Newsome and Professor Derek Manas to the meeting and they introduced themselves to the Committee.
6. The Chair welcomed company representatives from **Novartis** to the meeting.
7. The Chair asked all Committee members to declare any relevant interests
 - 7.1. Dr Jane Adam, Dr Graham Ash, Professor Aileen Clarke, Dr Jeremy Braybrooke, Dr Gerardine Bryant, Mr Adrian Griffin, Dr Anne McCune, Dr Mohit Misra, Dr Ian Lewin, Dr Brian Shine, Mr Stephen Sharp, Dr Eldon Spackman, Mr David Thomson, , Ellen Rule, Sarah Parry, Dr Andrew England, Dr Paul Robinson, Dr John Watkins, Professor Olivia Wu all declared that they knew of no personal specific pecuniary interest, personal non-specific pecuniary interest, non-personal specific pecuniary interest, non-personal non-specific pecuniary interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of Everolimus for preventing organ rejection in liver transplantation
 - 7.2. Professor Ian Squire declared a personal non-specific pecuniary interest as he has previously accepted honoraria payments for participation in Advisory Boards and Educational events sponsored by for Novartis in relation to cardiovascular health.

9.2.1 It was agreed that this declaration would not prevent Professor Ian Squire from participating in this section of the meeting.

8. The Chair asked all NICE Staff to declare any relevant interests.
 - 8.1. All declared that they knew of no personal specific pecuniary interest, personal non-specific pecuniary interest, non-personal specific pecuniary interest, non-personal non-specific pecuniary interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of Everolimus for preventing organ rejection in liver transplantation.
9. The Chair asked all other invited guests ERG and invited experts, not including observers) to declare their relevant interests.
 - 9.1. All declared that they knew of no personal specific pecuniary interest, personal non-specific pecuniary interest, non-personal specific pecuniary interest, non-personal non-specific pecuniary interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of **Everolimus for preventing organ rejection in liver transplantation**.
10. The Chair introduced the key themes arising from the consultation responses to the Appraisal Consultation Document (ACD) received from consultees, commentators and through the NICE website.
 - 10.1. The Committee then discussed the clinical effectiveness, patient perspective and cost effectiveness of **Everolimus for preventing organ rejection in liver transplantation** on the basis of the evidence before them, and potential equality issues raised in this appraisal. They sought clarification and advice from the experts present. The discussions included:
 - 10.2. Rationale and summary of the Committee's considerations for the draft recommendation in the appraisal consultation document
 - 10.3. Discussion of the Company's response to the consultation on the appraisal consultation document
 - 10.4. Whether the H2304 study was generalisable to UK clinical practice and the results from this study
 - 10.5. The company's additional evidence including the amendments to the network meta-analysis, to the assumptions in the economic model, and revised cost effectiveness results
 - 10.6. The Committee's view on the most plausible ICERs
11. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.
12. The Chair explained that "representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest" (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)" and all public attendees left the meeting.

13. The Chair then thanked the experts, company representatives and academic group for their attendance, participation and contribution to the appraisal and they left the meeting.

Part 2 – Closed session

14. Discussion on confidential information continued. This information was supplied by the company.
15. The Committee continued to discuss the clinical and cost effectiveness of Everolimus for preventing organ rejection in liver transplantation
16. The Committee instructed the technical team to prepare the Final Appraisal Determination (FAD) in line with their decisions.

Date, time and venue of the next meeting

17. **28th April 2015 at** Prospero House, 241 Borough High Street, London SE1 1GA)